Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TLRPROSTATE · Chemical programming of Toll like Receptor 4: Design, synthesis and biological studies of prostate-cancer vaccines

FP7Status: CLOSED5 January 20154 January 2018EU funding €341,387

The IOF proposal, TLRPROSTATE, consists of a 24 month outgoing phase to The Scripps Research Institute in San Diego, California, and a 12 month return phase to the Instituto de Productos Naturales y Agrobiología (IPNA-CSIC) for a total of 36 months. TLRPROSTATE will use advanced methods in synthetic biology to develop synthetic vaccines against prostate cancer, which is the second most common cancer worldwide for men. The project will consist of the design, synthesis and biological evaluation of synthetic vaccines that will chemically stimulate the toll-like receptors and therefore create an immune response. This exciting research area will increase Miranda’s expertise and knowledge in the field of synthetic biology as well as in the synthesis of complex organic molecules. During the return phase, Miranda will integrate his research findings into the studies carried out by the research group at IPNA. The return of knowledge and skills to the Canary Islands, Spain, will take place at a time when there is an increasing support from the government and also European authorities for the development of the Canary Islands as a nerve center in Biomedical studies through research programs partially financed by European funding.

Consortium · 1 organisation

coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €341,387

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.